ISpecimen Net Debt vs Non Current Assets Total Analysis
ISPC Stock | USD 4.44 0.14 3.06% |
ISpecimen financial indicator trend analysis is infinitely more than just investigating iSpecimen recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether iSpecimen is a good investment. Please check the relationship between ISpecimen Net Debt and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.
Net Debt vs Non Current Assets Total
Net Debt vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of iSpecimen Net Debt account and Non Current Assets Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between ISpecimen's Net Debt and Non Current Assets Total is -0.44. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of iSpecimen, assuming nothing else is changed. The correlation between historical values of ISpecimen's Net Debt and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of iSpecimen are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Net Debt i.e., ISpecimen's Net Debt and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | -0.44 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from ISpecimen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into iSpecimen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.As of November 24, 2024, Selling General Administrative is expected to decline to about 5.9 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 22.9 M
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.0M | 1.2M | 2.1M | 1.2M | Interest Income | 11.4K | 169.3K | 339.8K | 356.7K |
ISpecimen fundamental ratios Correlations
Click cells to compare fundamentals
ISpecimen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ISpecimen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.2M | 6.2M | 35.7M | 24.6M | 15.8M | 16.6M | |
Short Long Term Debt Total | 10.6M | 12.8M | 3.4M | 185.8K | 196.2K | 186.4K | |
Other Current Liab | 2.2M | 6.9M | 1.0M | 1.4M | 1.2M | 2.1M | |
Total Current Liabilities | 15.8M | 22.1M | 2.5M | 4.3M | 6.0M | 8.3M | |
Total Stockholder Equity | (22.7M) | (27.3M) | 29.8M | 20.3M | 9.7M | 10.2M | |
Net Tangible Assets | (25.0M) | (29.9M) | 27.1M | 15.8M | 18.2M | 19.1M | |
Property Plant And Equipment Net | 119.9K | 75.6K | 32.8K | 410.5K | 321.6K | 203.4K | |
Current Deferred Revenue | 2.2M | 873.3K | 654.7K | 132.3K | 415.8K | 687.7K | |
Net Debt | 10.5M | 12.1M | (24.3M) | (15.1M) | (2.1M) | (2.3M) | |
Retained Earnings | (24.4M) | (29.1M) | (38.0M) | (48.3M) | (59.4M) | (56.4M) | |
Accounts Payable | 737.8K | 1.8M | 832.7K | 2.5M | 3.9M | 4.1M | |
Cash | 53.9K | 695.9K | 27.7M | 15.3M | 2.3M | 2.2M | |
Non Current Assets Total | 2.6M | 2.7M | 2.8M | 4.9M | 7.6M | 4.1M | |
Cash And Short Term Investments | 53.9K | 695.9K | 27.7M | 15.3M | 5.0M | 9.2M | |
Net Receivables | 1.4M | 2.4M | 4.9M | 3.9M | 2.9M | 3.0M | |
Common Stock Shares Outstanding | 6.6M | 46.8K | 408.6K | 442.2K | 452.1K | 429.5K | |
Liabilities And Stockholders Equity | 4.2M | 6.2M | 35.7M | 24.6M | 15.8M | 16.6M | |
Other Current Assets | 79.2K | 417.9K | 327.0K | 300.4K | 292.1K | 278.1K | |
Other Stockholder Equity | (9.5M) | (9.4M) | 103.5M | 68.6M | 69.1M | 39.0M | |
Total Liab | 26.9M | 33.5M | 5.9M | 4.3M | 6.1M | 5.8M | |
Net Invested Capital | (12.1M) | (14.5M) | 33.2M | 20.3M | 9.7M | 10.2M | |
Property Plant And Equipment Gross | 119.9K | 75.6K | 340.1K | 410.5K | 766.4K | 804.7K | |
Total Current Assets | 1.6M | 3.5M | 32.9M | 19.7M | 8.2M | 12.5M | |
Net Working Capital | (14.2M) | (18.7M) | 30.4M | 15.4M | 2.2M | 1.1M | |
Intangible Assets | 2.3M | 2.6M | 2.7M | 4.5M | 7.2M | 3.8M | |
Property Plant Equipment | 119.9K | 75.6K | 32.8K | 410.5K | 472.1K | 495.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.12) | Revenue Per Share 19.19 | Quarterly Revenue Growth (0.04) | Return On Assets (0.44) | Return On Equity (1.09) |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.